Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 6/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.47 |
| ▸ | KHK | P50053 | 4/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307072 | 0.81 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AF10 | |
| SCHEMBL11217206 | 0.80 | KHK (0.62) | MEN1KMT2ANPC1RAB9AF10 | |
| SCHEMBL11236082 | 0.79 | F10 (0.69) | MEN1KMT2ANPC1RAB9AF10 | |
| SCHEMBL21150829 | 0.75 | POLB (0.48) | KMT2AF10F2PRSS1 | |
| SCHEMBL27175898 | 0.72 | KHK (0.52) | MEN1KMT2ANPC1RAB9AF10 | |
| SCHEMBL610584 | 0.72 | NPC1 (1.00) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28575596 | 0.72 | NPC1 (0.67) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL706165 | 0.71 | KMT2A (0.50) | MEN1KMT2ANPC1RAB9AF10 | |
| SCHEMBL31662436 | 0.71 | F10 (0.43) | MEN1KMT2ANPC1RAB9AF10 | |
| SCHEMBL706166 | 0.71 | KMT2A (0.50) | MEN1KMT2ANPC1RAB9AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | claimed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| CN-101679382-A | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | MEN1 323/4885KMT2A 1471/4885NPC1 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.